Goldman Sachs
SIOX

Goldman Sachs’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Goldman Sachs’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,355
Closed -$22K – 7073
2021
Q4 		$22K Buy
+17,355
New +$30.8K ﹤0.01% 6362
2020
Q4 		– Sell
-91,731
Closed -$424K – 5793
2020
Q3 		$424K Buy
+91,731
New +$303K ﹤0.01% 4567
2020
Q2 		– Sell
-26,839
Closed -$65K – 5561
2020
Q1 		$65K Buy
26,839
+15,901
+145% +$57.4K ﹤0.01% 5007
2019
Q4 		$56K Sell
10,938
-7,375
-40% -$40.9K ﹤0.01% 5109
2019
Q3 		$118K Buy
18,313
+7,582
+71% +$52.3K ﹤0.01% 4939
2019
Q2 		$67K Sell
10,731
-12,667
-54% -$96.4K ﹤0.01% 4989
2019
Q1 		$249K Buy
23,398
+17,611
+304% +$175K ﹤0.01% 4709
2018
Q4 		$46K Sell
5,787
-15,357
-73% -$221K ﹤0.01% 5102
2018
Q3 		$409K Sell
21,144
-9,496
-31% -$173K ﹤0.01% 4524
2018
Q2 		$554K Buy
30,640
+9,352
+44% +$138K ﹤0.01% 4448
2018
Q1 		$227K Sell
21,288
-1,547
-7% -$24.8K ﹤0.01% 4934
2017
Q4 		$963K Buy
22,835
+16,893
+284% +$758K ﹤0.01% 4358
2017
Q3 		$327K Sell
5,942
-5,586
-48% -$942K ﹤0.01% 5402
2017
Q2 		$2.14M Sell
11,528
-4,181
-27% -$733K ﹤0.01% 3784
2017
Q1 		$1.88M Sell
15,709
-6,890
-30% -$722K ﹤0.01% 3806
2016
Q4 		$2.25M Buy
22,599
+17,036
+306% +$1.79M ﹤0.01% 3746
2016
Q3 		$623K Buy
5,563
+3,891
+233% +$467K ﹤0.01% 4831
2016
Q2 		$172K Sell
1,672
-442
-21% -$44.2K ﹤0.01% 5813
2016
Q1 		$194K Buy
+2,114
New +$226K ﹤0.01% 5656

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Goldman Sachs's SIOX Position: Q1 2022 in Review

Goldman Sachs sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2022, closing a stake of 17,355 shares — an estimated $22K sold.

Goldman Sachs first reported a position in SIOX in Q1 2016 and held it in 19 quarters. The position peaked at $2.25M in Q4 2016. 41 funds tracked by Wall St. Rank hold SIOX as of Q1 2022.

  • Goldman Sachs reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Goldman Sachs sold 17,355 Sio Gene Therapies Inc. Common Stock shares in Q1 2022, an estimated $22K.
  • Goldman Sachs first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2016 and held it in 19 quarters.
  • Goldman Sachs's Sio Gene Therapies Inc. Common Stock position peaked at $2.25M in Q4 2016.
  • 41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.